20 November 2025 - Pharmac is asking for feedback on a proposal to fund another brand of methylphenidate to increase supply and provide more treatment options for people with attention deficit hyperactivity disorder.

If approved, the Rubifen LA (long-acting) brand of methylphenidate will be funded from 1 July 2026. This is a generic equivalent of the already funded Ritalin LA brand of methylphenidate and would be available in the same strengths, as well as a new 60 mg strength.

Read PHARMAC press release